The weight management market continues to grow

As obesity rates continue to rise worldwide, with more than 100 million Americans affected, SNS Insider analysts project the market for weight loss drugs to grow at an annual rate of 43.73% to in 2032.

This market, which is one of the fastest growing in medicine, sees almost one in four employers considering covering the cost of anti-obesity drugs in the next year.

Health and wellness companies, including PlantX Life Inc., Novo Nordisk A/S, Eli Lilly and Company, Viking Therapeutics, Inc., and Roche Holding AG, are responding to these events.

According to Morgan Stanley, the global market for obesity drugs is expected to increase more than 15 times in the next five years. Their benefits go beyond weight loss, which has great consequences for consumer goods and longevity.

The introduction of new weight loss drugs can accelerate as big pharma players enter the market.

PlantX Life Inc. announced a joint venture with LIV3 to launch the SugarShield supplement, targeting the US$5.24bn Weight Loss Management Supplement Market.

PlantX will manage SugarShield’s branding and packaging design while developing an e-commerce platform to support product development.

Marketing efforts will also be led by PlantX, using its SEO business strategies. Profits from the partnership will be split equally between PlantX and LIV3.

Lorne Rapkin, CEO of PlantX, said, “The growth of the weight loss supplement market has been fueled by the popularity of products that have been developed to treat type 2 diabetes. , we at PlantX see this as an opportunity to provide plant-based alternatives.”

Rapkin praised LIV3 founder Chris Mearns for developing what he described as ‘natural Ozempic’ with SugarShield.

The LIV3 supplement is designed to help users manage their weight by boosting energy and suppressing cravings without restricting diet.

Christopher Mearns, founder of LIV3, emphasized that SugarShield helps reduce uric acid and improve metabolic health without dietary changes. The supplement is positioned as a natural alternative to sugar-free foods.

Paul Gross, a member of the PlantX medical team, confirmed the science behind SugarShield, ensuring that the supplement is based on scientific research. Gross contributions have strengthened confidence in the potential of the supplement, supporting its launch with a guarantee of its effectiveness.

Novo Nordisk recently announced results from its SOUL trial, which showed that oral semaglutide (Rybelsus) reduced major adverse cardiovascular events (MACE) by 14 percent in adults with coronary artery disease. type 2 sugar.

This randomized study, which enrolled 9,650 participants, showed benefits beyond weight loss.

Meanwhile, Eli Lilly has taken legal action against medical spas and online retailers selling generic versions of tirzepatide, the main ingredient in its weight-loss drug. Zipbound. These cases are the first since the US Food and Drug Administration (FDA) removed tirzepatide from its short supply list.

Viking Therapeutics presented the first data on two agonists for obesity and metabolic disorders at the American Diabetes Association’s 84th Scientific Sessions. The data showed a significant reduction in body weight and food intake in obese mice.

Roche Holding AG reports that the top three obesity and diabetes patients can make more than $3.6bn a year.

These drugs are part of a broader pipeline that Roche expects will lead to the launch of 20 new drugs by the end of the decade, focusing on several therapeutic areas, including metabolic diseases.